ELEVATE UC 52 and UC 12UC · Induction and maintenance
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
Sandborn WJ, et al.
Lancet 2023 · PMID 36871574 (PubMed, opens in a new tab) · doi 10.1016/S0140-6736(23)00061-2 (full paper, opens in a new tab)
| Endpoint | Etrasimod 2 mg | Placebo | Difference |
|---|---|---|---|
| Clinical remission, UC 52 · week 12 (primary endpoint) | 27% (74/274) | 7% (10/135) | P<0.0001 |
| Clinical remission, UC 52 · week 52, treat-through (primary endpoint) | 32% (88/274) | 7% (9/135) | P<0.0001 |
| Clinical remission, UC 12 · week 12 (primary endpoint) | 25% (55/222) | 15% (17/112) | P=0.026 |
Because UC 52 was treat-through, its week-52 rate includes induction non-responders and is not comparable with randomised-withdrawal maintenance rates.
Source: Sandborn 2023, abstract. The abstract gives P values but no treatment differences or CIs.
Structured abstract
BackgroundS1P receptor modulators keep lymphocytes in lymph nodes; etrasimod, a once-daily oral agent selective for S1P receptors 1, 4 and 5, was tested as induction and maintenance therapy in UC.
MethodsTwo independent phase 3, randomised (2:1), double-blind, placebo-controlled trials: UC 52 (12-week induction plus 40-week maintenance, treat-through) and UC 12 (12-week induction). 787 patients. Primary endpoint: Clinical remission at weeks 12 and 52 (UC 52) and at week 12 (UC 12).
ResultsPrimary result. UC 52: week 12, 27% (74/274) vs 7% (10/135); week 52, 32% (88/274) vs 7% (9/135); both P<0.0001. UC 12: week 12, 25% (55/222) vs 15% (17/112); P=0.026.
Take-homeEtrasimod, a once-daily oral S1P modulator, induces and maintains remission in UC, shown in a stricter treat-through design.
| Patients | 787 |
|---|---|
| Population | Adults with moderately to severely active UC and inadequate response, loss of response or intolerance to at least one approved UC therapy (UC 52: 433; UC 12: 354). Stratified by prior biologic or JAK inhibitor use, steroid use and modified Mayo score (4–6 vs 7–9). |
| Comparison | Etrasimod 2 mg once daily vs placebo |
| Drugs | etrasimod |
| Classes | S1P receptor modulator |
| Published | Sandborn WJ, et al. Lancet 2023;401:1159–71. |
Key points
- Treat-through design: the week-52 result includes everyone randomised, not only induction responders, so it is a more conservative estimate than randomised-withdrawal trials.
- Adverse events: 71% vs 56% in UC 52 and 47% vs 47% in UC 12.
- No deaths or malignancies were reported.
- Etrasimod is selective for S1P receptor subtypes 1, 4 and 5.
Limitations
- UC 12 had a relatively high placebo remission rate (15%), narrowing the difference.
- No active comparator.
- Included some patients with modified Mayo score 4, at the milder end of moderate disease.
Commentary
Reading treat-through vs randomised-withdrawal results. In randomised-withdrawal trials (for example True North, PMID 34587385) only induction responders are re-randomised, so maintenance percentages look higher. ELEVATE UC 52 kept everyone on their original assignment, so its 32% week-52 remission rate is not directly comparable with withdrawal-design maintenance figures.
Canada. Etrasimod is marketed in Canada. S1P class precautions apply (heart rate at the start, macular oedema, liver enzymes, infections); follow the product monograph.
Journal club
Design
Two independent phase 3, randomised (2:1), double-blind, placebo-controlled trials: UC 52 (12-week induction plus 40-week maintenance, treat-through) and UC 12 (12-week induction). 787 patients.
Primary result. UC 52: week 12, 27% (74/274) vs 7% (10/135); week 52, 32% (88/274) vs 7% (9/135); both P<0.0001. UC 12: week 12, 25% (55/222) vs 15% (17/112); P=0.026.
Validity and applicability
- UC 12 had a relatively high placebo remission rate (15%), narrowing the difference.
- No active comparator.
- Included some patients with modified Mayo score 4, at the milder end of moderate disease.
Where it sits now
Etrasimod, a once-daily oral S1P modulator, induces and maintains remission in UC, shown in a stricter treat-through design.
- ASTRO (2026): Guselkumab can be started with subcutaneous 400 mg injections instead of IV infusions, with clear benefit over placebo by week 12.
- RELIEVE UCCD (UC) (2026): Duvakitug, an anti-TL1A antibody, showed a dose-related remission signal in UC in phase 2b; phase 3 trials will decide its place.
- QUASAR (2025): Guselkumab induces and maintains remission in UC, and the follow-up ASTRO trial showed induction can be given subcutaneously.
- TUSCANY-2 (2025): Afimkibart missed its phase 2b primary endpoint (total Mayo remission), although remission by the modified Mayo score favoured it; anti-TL1A therapy still needs phase 3 proof.
Questions for discussion
- The remission denominators (274 and 135) are smaller than the full analysis set (289 and 144). Find out who was left out of the primary analysis, and why it matters.
- Why does a treat-through week-52 rate of 32% not compare directly with maintenance rates from randomised-withdrawal trials such as True North?
- Which baseline checks and monitoring would you arrange before starting an S1P receptor modulator?